An observational study in Cirrhosis, Alcoholic Liver Disease and Alcoholic Hepatitis, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by Hospices Civils de Lyon · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Hepatitis, Alcoholic with a site in France — 5 open to participants now, 5 under way, 1 of them phase 3. Hepatitis, Alcoholic · France.
Among the 16 studies in Hepatitis, Alcoholic with a site in France, this one is one of 2 that started in 2024, is one of 3 observational ones, and was the 14th registered.
114 studies on the registry are indexed under Hepatitis, Alcoholic; 25 are open to participants now.
Browse Hepatitis, Alcoholic studies →5 of the 16 studies in Hepatitis, Alcoholic with a site in France are open now. Recruiting first, the newest first:
University Hospital, Lille · Sites in France
Ages 18–75
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18–75 · Healthy volunteers
University Hospital, Lille · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 17 Hepatitis, Alcoholic studies recruiting now, 9 (53%) set no upper age limit and 8 (47%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 230 across 28 observational studies indexed under Hepatitis, Alcoholic.
Median enrollment 174 across the 13 interventional studies, 447 across the 3 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 16 have an industry lead sponsor. The 10 most frequent:
Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.
Hospices Civils de Lyon has 1 study filed under Hepatitis, Alcoholic — fewer than ten, so there is no comparison to draw.
1 of the studies in Hepatitis, Alcoholic with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04106518University Hospital, LilleStudy of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Hepatitis, Alcoholic with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Alcoholic hepatitis (AH) is a serious complication of alcoholic liver disease (ALD). The histological presentation of AH is characterized by neutrophilic lobular inflammation, macrovesicular steatosis, hepatocyte ballooning and necrosis and the presence of Mallory bodies. In cases of severe HA, defined by a modified Maddrey score of 32 or above, mortality at 1 month is estimated at between 10 and 50%. The only treatment to reduce early mortality is corticosteroid therapy. However, only 60% of patients respond to corticosteroids, and no benefit has been demonstrated on late mortality. Identifying new therapeutic targets is therefore a major challenge in this disease.
Numerous pre-clinical studies and human data suggest the involvement of the intestinal microbiota in the pathogenesis of AH. Translocation of viable bacteria and microbial products from the digestive tract to the liver contributes to local and systemic inflammation, hepatocyte death and fibrogenesis. However, the intrahepatic microbial environment has never been characterized in HA.
The study hypothesis is that the intrahepatic microbiota is modulated by bacterial translocation and is associated with clinical outcomes.
The aim of this study is to determine the composition of the intrahepatic (obtained from transjugular liver biopsy), blood and fecal microbiota in patients with suspected severe AH from a monocentric prospective cohort in the Hepatology Department at Croix-Rousse Hospital (Lyon). Fifty consecutive patients with clinical suspicion of AH and indication for transjugular liver biopsy will be included. About thirty-five patients are expected in the confirmed AH group, and 15 in the group "alcoholic liver disease with no AH", based on data from the literature. The composition of the various microbiota will be determined by sequencing the 16S rRNA gene, and the results will be correlated with clinical data (corticosteroid sensitivity, overall survival, transplant-free survival, MELD score in particular) and histological data.
This exploratory study will enable to analyze the intra-hepatic microbiota, and to study its link with intra-hepatic inflammation and the clinical course of patients with AH. The data generated by HepMAH will thus help identify potential new therapeutic targets linked to the gut microbiota, and provide a scientific basis for the development of therapeutic interventions targeting the microbiota in HA.
114 studies on the registry are indexed under Hepatitis, Alcoholic; 25 are open to participants now.
This study's planned enrollment of 50 is below the median of 230 across 28 observational studies indexed under Hepatitis, Alcoholic.
Browse Hepatitis, Alcoholic studies →Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.
Compared within Hepatitis, Alcoholic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
A prospective observational multicentric cohort will be conducted at Croix Rousse Hospital (Lyon, France), in the Hepatology and Intensive Care Units.
Fifty consecutive patients hospitalized in either of these units for clinical suspicion of alcoholic hepatitis and indication for transjugular liver biopsy will be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with histologically proven AH (after transjugular liver biopsy procedure and histological assessment).
Procedure: Biological sampling
Patients with initially suspected AH (excessive alcohol consumption and modified Maddrey score \> 32) but no AH at the histological evaluation of liver biopsy. It corresponds to patients with decompensated alcoholic liver disease but no AH.
Procedure: Biological sampling
* A fragment of the diagnostic transjugular liver biopsy (D0) * Plasma samples at D0, and at 1 and 6 months after liver biopsy if possible * Fecal samples at D0, and at 1 and 6 months after liver biopsy if possible
Microbiota composition
Intrahepatic, blood and fecal microbiota composition will be assessed by 16S rRNA sequencing (MiSeq Illumina). Microbiota analysis will be performed on the fragment of transjugular liver biopsy collected for the purpose of the study, and on plasma and fecal samples after bacterial DNA extraction. Bioinformatics analysis will be carried out using Qiime2, LeFSE (Conda) and the Maaslin2 package (v3.16; R software). Microbiota profiles determined at the genus taxonomic level will be compared between the two groups (proven AH and no AH).
Time frame: At Day 0, 1 month and 6 months
Started Jul 2024 (actual). Primary completion is estimated for Jan 2028, 42 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.